Dexamethasone

Generic Name: Dexamethasone

Brand Names: Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₉FO_₅

CAS Number: 50-02-2

Unique Ingredient Identifier: 7S5I7G3JQL

Background: Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
...

Indication: Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, an...

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes

Associated Therapies: -

Clinical Trials

Evaluate the Neurological Effects of EryDex on Subjects With A-T

Phase 3

Recruiting

Conditions: Ataxia Telangiectasia

Interventions: Drug: Dexamethasone sodium phosphate
Other: Placebo

First Posted Date: 2024-01-05

Last Posted Date: 2024-12-19

Lead Sponsor: Quince Therapeutics S.p.A.

Target Recruit Count: 106

Registration Number: NCT06193200

Locations: 🇺🇸
University of California Los Angeles (UCLA), Ataxia Center and HD Center of excellence, Los Angeles, California, United States
🇺🇸
The Johns Hopkins Hospital, Division of pediatric allergy and immunology, Baltimore, Maryland, United States
🇺🇸
Cincinnati Children's Hospital, Division of neurology, Cincinnati, Ohio, United States

and more 16 locations

Establishment and Evaluation of Prenatal Prevention and Treatment Strategy for NARDS

Not Applicable

Not yet recruiting

Conditions: Acute Respiratory Distress Syndrome
Respiratory Distress Syndrome, Acute

Interventions: Drug: Dexamethasone

First Posted Date: 2024-01-03

Last Posted Date: 2024-01-26

Lead Sponsor: The Second Affiliated Hospital of Chongqing Medical University

Target Recruit Count: 500

Registration Number: NCT06188195

FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)

Phase 3

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Daratumumab Injection
Drug: Dexamethasone
Drug: Lenalidomide capsule

First Posted Date: 2024-01-02

Last Posted Date: 2024-08-19

Lead Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland

Target Recruit Count: 599

Registration Number: NCT06187441

Locations: 🇳🇱
NL-Amsterdam- UMC, Amsterdam, Netherlands
🇳🇱
NL-Amsterdam-AmsterdamUMC, Amsterdam, Netherlands
🇳🇱
Nij Smellinghe Ziekenhuis, Drachten, Netherlands

and more 35 locations

Intraligamentary Injections and Post-endodontic Pain

Not Applicable

Recruiting

Conditions: Pulpitis

Interventions: Drug: Dexamethasone

First Posted Date: 2024-01-02

Last Posted Date: 2024-01-02

Lead Sponsor: Jamia Millia Islamia

Target Recruit Count: 140

Registration Number: NCT06186921

Locations: 🇮🇳
Faculty of Dentistry, Jamia MIliia Islamia, New Delhi, India

Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma

Phase 3

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Daratumumab
Drug: Dexamethasone

First Posted Date: 2023-12-27

Last Posted Date: 2024-12-11

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 559

Registration Number: NCT06182774

Locations: 🇨🇦
BCCA - Kelowna, Kelowna, British Columbia, Canada
🇨🇦
Verspeeten Family Cancer Centre, London, Ontario, Canada
🇨🇦
Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada

and more 15 locations

Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL

Not yet recruiting

Conditions: Philadelphia-Positive ALL
Lymphoblastic Leukemia
Adult ALL

Interventions: Drug: Vincristine
Drug: Dexamethasone
Drug: Imatinib
Drug: Cytarabine
Drug: Mercaptopurine
Drug: Methotrexate
Drug: Ponatinib
Procedure: allogeneic stem cell transplantation
Procedure: Total body irradiation
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2023-12-19

Last Posted Date: 2023-12-19

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 150

Registration Number: NCT06175702

Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune Thrombocytopenia

Phase 2

Recruiting

Conditions: Immune Thrombocytopenia

Interventions: Drug: Teriflunomide
Drug: Dexamethasone

First Posted Date: 2023-12-19

Last Posted Date: 2023-12-26

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 132

Registration Number: NCT06176235

Locations: 🇨🇳
China-Japan Friendship Hospital, Beijing, China
🇨🇳
Chinese PLA General Hospital, Beijing, China
🇨🇳
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, China

and more 7 locations

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Phase 2

Recruiting

Conditions: Multiple Myeloma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Drug: Bortezomib
Procedure: Computed Tomography
Biological: Daratumumab
Drug: Daratumumab and Recombinant Human Hyaluronidase
Drug: Dexamethasone
Drug: Lenalidomide
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Drug: Selinexor

First Posted Date: 2023-12-13

Last Posted Date: 2024-10-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 70

Registration Number: NCT06169215

Locations: 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸
Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States
🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States

and more 23 locations

A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Alnuctamab
Drug: Mezigdomide
Drug: Dexamethasone

First Posted Date: 2023-12-11

Last Posted Date: 2024-10-21

Lead Sponsor: Celgene

Target Recruit Count: 156

Registration Number: NCT06163898

Locations: 🇺🇸
Local Institution - 0035, New Haven, Connecticut, United States
🇺🇸
Local Institution - 0018, New York, New York, United States
🇺🇸
Local Institution - 0033, Birmingham, Alabama, United States

and more 3 locations

Comparative Assessment of Preoperative Versus Postoperative Submucosal Dexamethasone on Postoperative Complications Following Surgical Extraction of Mandibular Third Molar: Randomized Controlled Trial

Phase 4

Not yet recruiting

Conditions: Pain, Postoperative

Interventions: Drug: Dexamethasone

First Posted Date: 2023-12-07

Last Posted Date: 2024-08-09

Lead Sponsor: B.P. Koirala Institute of Health Sciences

Target Recruit Count: 60

Registration Number: NCT06160180

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy